Statements (57)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:drug
|
| gptkbp:bfsLayer |
4
|
| gptkbp:bfsParent |
gptkb:Sanofi_Genzyme
gptkb:Sanofi_Aventis |
| gptkbp:activities |
pyrimidine synthesis inhibitor
|
| gptkbp:approves |
gptkb:2012
|
| gptkbp:associated_with |
improved quality of life
decreased lesion formation reduced MRI activity reduction in relapses slowing of disability progression |
| gptkbp:brand |
gptkb:teriflunomide
|
| gptkbp:class |
immunomodulator
|
| gptkbp:clinical_trial |
Phase III
long-term treatment |
| gptkbp:contraindication |
pregnancy
other immunosuppressants severe liver impairment |
| gptkbp:dosage_form |
gptkb:tablet
|
| gptkbp:effective_date |
September 2012
|
| gptkbp:formulation |
film-coated tablet
|
| gptkbp:has_ability |
7 mg
14 mg |
| https://www.w3.org/2000/01/rdf-schema#label |
Aubagio
|
| gptkbp:ingredients |
gptkb:teriflunomide
|
| gptkbp:invention |
2028
|
| gptkbp:is_available_in |
tablet form
two strengths |
| gptkbp:is_available_on |
generic version
|
| gptkbp:is_monitored_by |
blood pressure
liver function |
| gptkbp:is_used_for |
gptkb:psychologist
|
| gptkbp:manager |
oral
|
| gptkbp:manufacturer |
gptkb:Sanofi
|
| gptkbp:marketed_as |
gptkb:legislation
gptkb:United_States gptkb:Native_American_tribe |
| gptkbp:population |
adults
children over 12 |
| gptkbp:requires |
available online
potential side effects blood pressure monitoring liver monitoring |
| gptkbp:side_effect |
fatigue
headache nausea abdominal pain diarrhea liver damage hair loss increased blood pressure upper respiratory tract infection |
| gptkbp:storage |
room temperature
|
| gptkbp:suitable_for |
patients with severe renal impairment
patients with active infections patients with hypersensitivity to teriflunomide |
| gptkbp:traded_on |
gptkb:Aubagio
|